P-BCMA-101

Drug Profile

P-BCMA-101

Alternative Names: B-cell-maturation antigen-specific CAR T-cells; CARTyrin T cell product; P BCMA 101

Latest Information Update: 03 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poseida Therapeutics
  • Developer Janssen Biotech; Poseida Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple myeloma
  • Preclinical Solid tumours

Most Recent Events

  • 27 Sep 2017 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in USA (Parenteral) (NCT03288493; 9223569)
  • 22 May 2017 Poseida Therapeutics in-licenses UniDab™ technology from TeneoBio
  • 04 Apr 2017 Preclinical data in Multiple myeloma presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top